Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

NCT04586023 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

751

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Multiple Sclerosis

Interventions

DRUG: Fenebrutinib
DRUG: Teriflunomide
DRUG: Placebo

Sponsor

Hoffmann-La Roche